Molnupiravir is an oral antiviral agent, at the moment being studied in a Phase three trial for the therapy of non-hospitalised COVID-19 sufferers
New Delhi: Drug agency MSD has determined to enter into voluntary licensing agreements for investigational oral antiviral drug candidate ‘molnupiravir’, which is being studied for the therapy of COVID-19 , with Indian drug companies Sun Pharma, Cipla, Dr Reddy’s, Emcure Pharma and Hetero Labs, its Indian arm stated on Tuesday.
Molnupiravir is an investigational oral antiviral agent, at the moment being studied in a Phase three trial for the therapy of non-hospitalised sufferers with confirmed COVID-19 , MSD India stated in a press release.
MSD India is an entirely owned subsidiary of Merck Sharp & Dohme (MSD) and often known as Merck & Co, Inc, within the United States and Canada.
MSD has determined to enter into non-exclusive voluntary licensing agreements for molnupiravir with 5 established Indian generic producers – Cipla, Dr Reddy’s Laboratories, Emcure Pharmaceuticals, Hetero Labs and Sun Pharmaceutical Industries, it added.
These 5 producers have World Health Organization (WHO) Pre-Qualified Manufacturing amenities and expertise as main suppliers to world and key low and middle-income nations (LMICs) procurers, MSD India stated.
MSD has entered into these agreements to speed up availability of molnupiravir in India and in different LMICs following approvals or emergency authorisation by native regulatory businesses, it added.
“These agreements, toward which we have been working as we have been studying molnupiravir, will help to accelerate access to molnupiravir in India and around the world,” Merck & Co, Inc, US Chairman and CEO Kenneth C Frazier stated.
“We remain committed to aiding in the global response that will bring relief to the people of India and, ultimately, bring an end to the pandemic,” he added.
Under the agreements, Merck & Co, Inc, US will present licences to those producers to produce molnupiravir to India and greater than 100 LMICs. The firm can also be in discussions with the Medicines Patent Pool to discover the potential for extra licenses, the assertion stated.
“Through partnerships with established Indian generics manufacturers, we are reinforcing our commitment towards expanding access to molnupiravir in India,” MSD-India Region MD Rehan A Khan stated.
Merck & Co, Inc will even donate greater than USD 5 million value of oxygen-production gear, masks, hand sanitiser and monetary support to assist aid efforts in India, the assertion stated.